Lenumlostat

CAS No. 2098884-52-5

Lenumlostat( —— )

Catalog No. M36314 CAS No. 2098884-52-5

Lenumlostat is an orally available, selective and potent lysyl oxidase-like protein 2 (LOXL2) inhibitor with inhibitory effects on hLOXL2, hLOXL3 and LOXL2 for the study of fibrotic diseases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 299 Get Quote
5MG 472 Get Quote
10MG 710 Get Quote
25MG 1371 Get Quote
50MG 2134 Get Quote
100MG 2988 Get Quote
500MG 6003 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Lenumlostat
  • Note
    Research use only, not for human use.
  • Brief Description
    Lenumlostat is an orally available, selective and potent lysyl oxidase-like protein 2 (LOXL2) inhibitor with inhibitory effects on hLOXL2, hLOXL3 and LOXL2 for the study of fibrotic diseases.
  • Description
    Lenumlostat is an orally available, selective and potent lysyl oxidase-like protein 2 (LOXL2) inhibitor with inhibitory effects on hLOXL2, hLOXL3 and LOXL2 for the study of fibrotic diseases.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    Monoamine Transporter
  • Recptor
    Monoamine Oxidase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2098884-52-5
  • Formula Weight
    399.34
  • Molecular Formula
    C18H17F4N3O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O(C=1N=C(C(F)(F)F)C=C(CN)C1)C2=CC(C(=O)N3C[C@@H](F)[C@H](O)C3)=CC=C2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Lenumlostat

    Lenumlostat is an orally available, selective and potent lysyl oxidase-like protein 2 (LOXL2) inhibitor with inhibitory effects on hLOXL2, hLOXL3 and LOXL2 for the study of fibrotic diseases.

  • Vanoxerine

    Vanoxerine (GBR-12909, I-893, Boxeprazine) is a highly potent inhibitor of dopamine uptake in vitro in tissue slices obtained from rat neostriatum with IC50 of 40-50 nM.

  • Edivoxetine

    Edivoxetine (LY2216684) is a novel potent, selective norepinephrine reuptake inhibitor (NERI) being evaluated as adjunctive treatment for major depressive disorder (MDD).